WHAT'S NEXT? If you suffered a loss in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP during the relevant time frame, you have until September 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. NEW YORK, Aug. 5, 2025 /P ...

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1 ...

诉讼核心信息 - 律师事务所Levi & Korsinsky, LLP就Neogen Corporation（NASDAQ: NEOG）的证券集体诉讼通知投资者 [1] - 该诉讼旨在为在2023年1月5日至2025年6月3日期间因涉嫌证券欺诈而遭受不利影响的投资者挽回损失 [1] - 投资者可在2025年9月16日前请求法院指定其为首席原告 [3] 诉讼指控细节 - 指控称被告发布了一系列重大虚假和误导性陈述，让投资者相信公司与3M公司食品安全部门的整合进展比实际情况要好 [2] - 即使在公司被迫披露整合中出现某些“低效率”问题时，被告仍淡化问题并向投资者保证他们已充分了解并承诺迅速解决 [2] 律所背景 - Levi & Korsinsky律师事务所在过去20年间已为受损股东争取到数亿美元赔偿，并拥有赢得高风险案件的记录 [4] - 该律所在复杂证券诉讼中代表投资者方面拥有广泛专业知识，拥有超过70名员工的团队 [4] - 连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼律所之一 [4]

诉讼背景 - Levi & Korsinsky律所针对PepGen Inc（NASDAQ: PEPG）投资者发起证券集体诉讼，旨在为2024年3月7日至2025年3月3日期间因涉嫌证券欺诈遭受损失的投资者追回损失 [1] 指控内容 - 公司主打候选产品PGN-EDO51的实际有效性和安全性低于管理层向投资者传达的水平 [2] - 第二阶段CONNECT2研究存在设计缺陷或安全隐患，可能无法满足美国食品药品监督管理局（FDA）的批准要求 [2] - 上述问题导致公司可能中止CONNECT2研究，且PGN-EDO51的临床、监管及商业前景被夸大 [2] - 公司公开声明在诉讼期间存在重大虚假和误导性内容 [2] 程序安排 - 受影响投资者需在2025年8月8日前向法院申请作为首席原告 [3] - 参与赔偿无需支付任何自付费用，且无需承担首席原告职责 [3] 律所资质 - Levi & Korsinsky过去20年为股东追回数亿美元损失，拥有70人以上专业团队 [4] - 连续七年被ISS证券集体诉讼服务评为美国前50大证券诉讼律所 [4]

https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=159580&wire=4 LMT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reporting of its risk adjusted profit booking rate; (2) Lockheed Martin lacke ...

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sable Offshore Corp. ("Sable Offshore Corp." or the "Company") (NYSE: SOC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sable Offshore Corp. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2 ...

诉讼概述 - Levi & Korsinsky律师事务所通知Alto Neuroscience Inc (NYSE: ANRO)的投资者有关一项证券集体诉讼[1] - 该诉讼旨在为因涉嫌证券欺诈而遭受损失的投资者挽回损失[2] 集体范围 - 集体包括所有在2024年2月2日左右公司首次公开募股中根据招股说明书购买或收购Alto普通股的个人和实体[2] - 集体也包括在2024年2月2日至2024年10月22日期间（含首尾两日）购买或收购Alto证券的所有个人和实体[2] 指控内容 - 指控称被告做出虚假陈述和/或隐瞒事实，即公司产品管线ALTO-100在治疗重度抑郁症方面的效果不如被告向投资者所宣称的那样有效[3] - 因此，ALTO-100的临床、监管和商业前景被夸大[3] - 结果导致Alto的业务和/或财务前景被夸大[3] - 公司公开声明在所有相关时间都存在重大虚假和误导性[3] 后续步骤 - 在相关时间段内遭受损失的投资者可在2025年9月19日前请求法院指定其为首席原告[4] - 作为集体成员，可能有资格获得补偿而无需支付任何自付费用[4]

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our ...

诉讼背景 - Levi & Korsinsky律师事务所代表2024年9月17日至2025年5月26日期间因证券欺诈遭受损失的Rocket Pharmaceuticals投资者提起集体诉讼 [1] - 诉讼指控公司在上述期间发布虚假和误导性陈述 同时隐瞒重大不利事实 [2] 指控核心内容 - 公司被指控隐瞒RP-A501临床试验的真实安全性问题和方案修改 包括已知的严重不良事件（SAE）及参与者死亡风险 [2] - 公司在未向股东披露的情况下修改试验方案 在预处理方案中引入新型免疫调节剂 [2] - 2025年5月27日 FDA因至少一名患者在方案实质性修改后出现严重不良事件（最终死亡）而对RP-A501二期关键研究实施临床暂停 [2] - 公司承认方案修改决定在"数月前"已做出 但直到严重不良事件发生后才试图提醒投资者或公众 [2] 市场影响 - 消息公布后公司股价从2025年5月23日收盘价6.27美元/股暴跌至2025年5月27日2.33美元/股 单日跌幅约37% [2] 法律程序 - 受影响投资者可在2025年8月11日前向法院申请担任首席原告 [3] - 集体成员可能无需支付自付费用即可获得补偿 [3] 律师事务所背景 - Levi & Korsinsky过去20年为受损股东追回数亿美元 拥有70多名员工的专业团队 [4] - 连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼事务所之一 [4]

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit-subm ...